LabGenius

EXCITING NEWS! 📣 Today we announce LabGenius’ £35 million Series B fundraise! 🎉 The round was led by M Ventures with participation from new investors Octopus Ventures, LG Corp. and Recode Ventures alongside existing investors Atomico, Kindred Capital VC, Lux Capital and Obvious Ventures. The proceeds from the round will enable us to further advance our ML-driven antibody discovery platform and progress a pipeline of multispecific antibodies for the treatment of solid tumours towards the clinic. As part of this fundraise, we welcome Oliver Hardick (M Ventures) and Oliver Sims (Octopus Ventures) to the Board. They will serve alongside current Board members Edwin Moses (Chairman), Irina Elena Haivas (Atomico) and Leila Rastegar Zegna (Kindred). 🗞️ For more details on the round, check out the press release here - https://lnkd.in/erQrPsTE 💡Our CEO, James Field, shares his personal perspective on what this financing means for LabGenius here - https://lnkd.in/eKZen4rm

I am delighted to see LabGenius recognised as one of the UK's top 25 start ups to watch by Bloomberg. There's a chance I am biased...but I completely agree! Keep an eye on them as they develop better #multispecific #antibody drugs for diseases using #AI. https://lnkd.in/eBU4q_qt Also well done to ORCA Computing from Octopus Ventures deeptech portfolio. Delivering the world #photonic #quantum computing systems. And a special shoutout to Sano Genetics and Patrick Short, who i've watched build Sano over the years. Exciting to see you and the team recognised as well!

I am looking forward to speaking at #BioLogicSummit (January 13 - 16, San Diego) on our work at LabGenius using ML to optimise T-cell engagers for selective killing of tumor cells. Hope to see you there!

We're looking for an enthusiastic and skilled IT Technician to join our brilliant team! ✨ The IT Technician role is responsible for maintaining the company's IT infrastructure, providing technical support to employees, and ensuring the smooth operation of all IT-related activities. 💻 If this sounds like the opportunity for you, please apply here: https://lnkd.in/eyPERe2s

Last week at LabGenius, we hosted a Macmillan Coffee Morning at our London office in support of Macmillan Cancer Support, an organisation that provides invaluable practical, emotional, and financial assistance to people living with cancer across the UK. Thanks to the team's amazing cakes and bakes we raised over £1,000 for this cause, which is close to our hearts both personally and professionally. At LabGenius, we’re combining machine learning with high-throughput experimentation to accelerate the discovery of complex therapeutic antibodies, ultimately aiming to provide better treatment options for patients. 💚

🔬 🧫 🧬 Don’t miss out on an exclusive roundtable discussion on "Developing Therapies that Target Multiple Immune Pathways" at the Antibody Therapeutics Xchange - Brussels! 🗓 18 Nov 2024 | 09:05 - 10:05 CET 📍 Bi/Multispecifics Track Key topics include: ✅ Optimal design for a multispecific TCE - what have we learned, and what’s next? ✅ Improving tumor selectivity - do we need new combinations of TAAs? ✅ Checkpoint inhibition - address it in the same molecule or separately? 🔑 Led by Leonard Wossnig, CTO at LabGenius an expert in AI, quantum machine learning, and computational drug design. 💡 Secure your FREE spot! https://lnkd.in/eQWzNrAH Only available for Senior Scientists and above, from Bio and Pharma companies, with a drug pipeline. 💊 #AntibodyTherapeutics #BiSpecifics #Multispecifics #CancerResearch #Immunotherapy #AIInHealthcare #LabGenius #DrugDiscovery #PrecisionMedicine #ImmunePathways #TCellEngagers #CheckpointInhibition #Oncology #Pharma #Biotech #HealthcareInnovation #Xchange2024 #PharmaTech #Biopharma #Brussels2024 #ScientificRoundtable #hubXchange #Xchanges #Roundtable #FreePass #RegisterNow #ComplimentaryPass

We're pleased to announce that James Field, CEO of LabGenius will be speaking at SynbiTECH 2024! LabGenius is a next-generation antibody discovery company that has pioneered the development of an ML-driven antibody engineering platform that’s capable of designing, conducting and critically learning from its own experiments. As CEO, James has raised >$70M in financing from top-tier VCs and struck R&D deals with top pharma companies like Sanofi. Secure your ticket now: https://lnkd.in/ek2Mxww6 #SynbiTECH24 #SynBio #SyntheticBiology

What can AI really do in drug discovery? 🧠 Everyone agrees in the industry that AI has revolutionized biotech and that it is not done disrupting the market. But are there areas where the hype doesn’t meet expectations?👀 In this week’s podcast, Labiotech discussed the topic of AI in drug discovery with LabGenius founder and CEO, James Field. 🎤🎧 Tune into the latest episode of the Beyond Biotech Podcast to find out more! ⬇️ https://lnkd.in/d-DrBWqM #BeyondBiotechPodcast #AIdrugdiscovery #biotechinnovation #AIinbiotech #healthcarerevolution #biotechtrends #futureofmedicine

Following the news of their £35M funding round, I sat down with James Field, CEO and founder of LabGenius for the latest episode of What's Next. LabGenius is on a mission to not only help find novel treatments for cancer and other illnesses, but to use AI to augment the scientific method itself. In this episode we discuss: - how he went from academic lab to CEO & founder 👨🎓 - the critical role grants, angels and investors have played 💰 - the breakthroughs in AI that have accelerated LabGenius's progress to find novel therapeutics ⚗ - how AI will augment scientists, and change the way science is done 🔬 Check it out on Youtube and your favourite podcasting platforms below:

📖 Antibody discovery and development has progressed considerably, with machine learning offering a promising way to improve the process. But challenges remain with the application of ML - often due to a lack of rigorous model training and evaluation, or bad data practices. 💡 In their latest paper, published in Drug Discovery Today, Sandeep Kumar (Moderna), Andrew Buchanan (AstraZeneca), Norbert Furtmann (Sanofi), Victor Greiff(University of Oslo) and Leonard Wossnig (LabGenius) discuss best practices for each stage of the ML process to enhance data quality and reproducibility, and improve overall progress. Learn: - How to implement best practices for data generation and collection.  - Ways of processing data to get the best ML predictions. - How to rigorously evaluate ML models.  👉 https://lnkd.in/d7kaahDp